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Abstract
Keloid scars are often described as having an actively growing peripheral margin with a regressing centre. The aim of this 
study was to examine the possible heterogeneity within keloids and the involvement of different regions within and around 
keloid scars in the pathogenesis, using an in vitro keloid scar model. In vitro skin models were constructed from keratino-
cytes and fibroblasts from normal skin and different regions within and around keloid scars: periphery, centre, and (adjacent) 
surrounding-normal-skin regions. Additionally, fibroblasts were isolated from the superficial-central and deep-central regions 
of the keloid and combined with central keratinocytes. All keloid regions showed increased contraction compared to normal 
skin models, particularly in central regions. Myofibroblasts were present in all keloid regions but were more abundant in 
models containing central-deep keloid fibroblasts. Secretion of anti-fibrotic HGF and extracellular matrix collagen IV gene 
expression was reduced in the central deep keloid compared to normal skin. No significant differences between peripheral and 
central regions within keloids were observed for inflammatory cytokine CCL20, CCL27, CXCL8, IL-6 and IL-18 secretion. 
Parameters for surrounding-normal-skin showed similarities to both non-lesional normal skin and keloids. In conclusion, 
a simple but elegant method of culturing keloid-derived keratinocytes and fibroblasts in an organotypic 3D scar model was 
developed, for the dual purpose of studying the underlying pathology and ultimately testing new therapeutics. In this study, 
these tissue engineered scar models show that the central keloid region shows a more aggressive keloid scar phenotype than 
the periphery and that the surrounding-normal-skin also shares certain abnormalities characteristic for keloids.
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Introduction
Keloid formation is an unfortunate complication of wound 
healing in which raised scar tissue proliferates beyond the 
boundaries of the original lesion [22]. This type of excessive 
scar tissue develops as an abnormal wound healing response 
to cutaneous injury [10, 22, 23]. Research on its pathogen-
esis has yet to uncover the etiology behind keloid forma-
tion and consequently our understanding of the mechanisms 
responsible for keloid development is limited. This is clearly 
illustrated by the inability of current treatment methods to 
satisfactorily manage keloids [3, 22]. As keloids develop 
exclusively in humans [29, 35] and research on their patho-
genesis cannot be conducted solely on an intact original 
specimen, the need for a life-like in vitro model is evident.
Recently, we have demonstrated that keratinocytes and 
fibroblasts derived from human scars can be used to con-
struct a full thickness skin model in vitro which shows 
resemblance to the native scar [16]. The keloid scar model 
shared several abnormalities with the hypertrophic scar 
model, but more importantly, differences were identified 
between these two abnormal scar types (hypertrophic scar 
and keloid). For the construction of these scar models, 
the scar tissue was used in its entirety. However, clinical 
observations suggest that keloids are not simply homog-
enous outgrowths. The distinction most often employed is 
that between the periphery and the centre of a keloid. The 
peripheral margin of the keloid is often described as being 
elevated, more red in color, actively proliferating and invad-
ing the surrounding normal skin; while the central region 
is seen as less elevated, lighter toned and clinically regres-
sive over time [9, 13, 20, 24]. Differences have also been 
reported between keloid derived fibroblasts from peripheral 
or central regions when cultured in vitro with respect to 
lipid membrane composition [19], expression of apoptosis 
and extracellular matrix (ECM) related gene [24], collagen 
production [27], growth characteristics [20, 28], cell cycle 
distribution & regulation [8, 28, 30] and apoptosis-related 
protein expression [13, 20]. While the majority of published 
studies support the notion of an active periphery and a more 
quiescent centre, the opposite has also been reported with 
the central region thought to be the driving force behind 
keloid formation [28, 30]. Regardless, both concepts sug-
gest that heterogeneity probably exists within a keloid scar, 
a finding that should not be ignored by those studying the 
mechanisms responsible for keloid formation.
As keloids are defined by their invasive growth into 
adjacent normal skin, it seems likely that the normal skin 
directly adjacent to keloids may in fact not truly be ‘normal’ 
and could, therefore, also play a role in keloid pathogen-
esis. Increased erythema in the normal skin directly adja-
cent to the keloid scars is often observed, and in a perfusion 
imaging study, blood flow in keloids and adjacent skin was 
indeed significantly higher than in nonadjacent normal skin 
[18]. Itching has also been reported to extend to peri-keloi-
dal normal-appearing skin [14]. Taken together, these clini-
cal observations suggest the skin directly adjacent to keloid 
scars may also be involved in keloid scar formation.
Given the aforementioned differences within keloid scars 
and the possible involvement of surrounding skin, we sus-
pect that these different regions may differentially contribute 
to keloid scar formation. However, to our knowledge this 
has not yet been studied in a human, in vitro 3D scar model. 
In this study, we present an in vitro keloid scar model in 
which the different regions within and around the keloid scar 
can be studied and compared to unaffected normal skin to 
gain insight into keloid scar formation. The models serve a 
dual purpose of studying the underlying pathology and ulti-
mately testing new therapeutics. To this end, the constructed 
in vitro models were compared to non-lesional skin with 
respect to the following scar parameters: contraction, epi-
dermal and dermal thickness, expression of epidermal and 
dermal cell markers (Ki67, keratin 10, involucrin, vimentin, 
α-SMA), ECM gene expression and wound healing mediator 
secretion.
Materials and methods
Normal skin (Nskin) was obtained from patients undergo-
ing body contouring surgery to remove excess skin. Keloid 
scars (Kscar) were obtained from patients undergoing scar 
removal via excision and were selected by an experienced 
scar expert (plastic surgeon, author FBN). All scars used 
were at least 1 year old and had matured (with exception 
of one keloid donor: 6 months old). See Table 1 for donor 
characteristics.
Cell culture and construction of skin models
After removal of subcutaneous fat and any other soft tissue 
until the typical firm and rubbery keloid consistency was 
reached, keloids were further subdivided into peripheral 
(P-Kscar), central superficial (Cs-Kscar) and central deep 
(Cd-Kscar) regions (Fig. 1a–c). Dermal tissue until ± 0.5 cm 
depth was included for cell isolation, Cs-Kscar and Cd-Kscar 
samples were obtained from the upper and lower central 
half, respectively. If present, any extralesional normal skin 
directly adjacent to the keloid (sNskin) was also included. 
sNskin extended to approximately ± 0.5 cm beyond P-Kscar 
(see area between edge of keloid and dotted line in Fig. 1a, 
b). In contrast to sNskin which was always derived from 
keloid patients, normal skin (Nskin) was obtained from unaf-
fected control subjects. Keratinocytes and fibroblasts were 
isolated and cultured essentially as described previously 
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[32, 34]. Skin models were constructed in duplicate from 
keratinocytes (P2) and fibroblasts (P2-3) essentially as previ-
ously described [32] 21 (Fig. 1d). In brief, 4 × 105 Fibroblasts 
were seeded onto 2.2 × 2.2 cm squares of MatriDerm® (dr. 
Suwelack Skin & Health Care, Billerbeck, Germany) with 
FSM-I and cultured submerged in FSM-II for 3 weeks in 
0.4 µm pore size transwells (Costar Corning Inc., New York, 
NY, USA) in a 37 °C, 5%  CO2 atmosphere. Keratinocytes 
(P2) were then seeded on top of the fibroblast-populated 
MatriDerm® and cultured submerged in KC-I for 3–4 days, 
prior to culturing at an air–liquid interface in deep-well 
plates (BD Biosciences, Bedford, MA, USA) in KC-II for 
an additional 10 days. Upon addition of keratinocytes, SE 
were cultured in a 37 °C, 7.5%  CO2 atmosphere. Medium 
was changed twice a week. See supplementary table 1 for 
contents of culture media (KC-I, KC-II, FSM-I, and FSM-
II) used.
Wound contraction
Wound contraction is expressed as a reduction in surface 
area of the skin models at the end of the culture period. 
Surface area  (mm2) was determined in photographs of skin 
models at the time of harvesting (5 weeks culture), using 
NIS-Elements AR 2.10 imaging software.
Histological analysis
Paraffin tissue sections (5 µm) were stained with Haema-
toxylin & Eosin (HE) for histologic evaluation and deter-
mination of epidermal and dermal thickness. Epidermal 
thickness quantified by counting the number of keratino-
cyte cell layers at three random points in each skin model 
section (200× magnification). Dermal thickness measured 
using NIS-elements software to calculate length in µm at five 
random points per skin model section (100× magnification).
Table 1  Tissue and donor characteristics
Overview of the characteristics of the tissue used for this study. All the skin models were constructed using donor matched keratinocytes and 
fibroblasts, note that all the tissues with the same donor number originate from the same patient
NA not applicable, yr(s) year(s), mo months, Nskin normal skin (n = 8), P-Kscar peripheral keloid (n = 8), Cs-Kscar central superficial keloid 
(n = 7), Cd-Kscar central deep keloid scar (n = 7), sNskin surrounding normal skin (n = 5), − no information available. See Table 3 for further 
clarification of skin model donor matching and number of biological replicates (‘n’) per experiment
Donor Tissue Location Etiology Age Previous treatment Skin color Pt age Gender
1 Nskin Breast NA NA NA − 40 yrs Male
2 Nskin Breast NA NA NA White 34 yrs Male
3 Nskin Abdomen NA NA NA Dark brown − Female
4 Nskin Abdomen NA NA NA White 59 yrs Female
5 Nskin Abdomen NA NA NA − 49 yrs Female
6 Nskin Breast NA NA NA Dark brown 20 yrs Female
7 Nskin Leg NA NA NA White − −
8 Nskin Abdomen NA NA NA Dark brown 39 yrs Female
Kscar is subdivided into P-Kscar, Cs-Kscar and Cd-Kscar
9 Kscar Earlobe Piercing 4 yrs None Light brown 46 yrs Female
10 Kscar Neck Insect bite 8 yrs Excision; Corticosteroids Dark brown 15 yrs Female
11 Kscar Abdomen Surgery 6 mo None Dark brown 23 yrs Female
12 Kscar Earlobe Piercing 1 yr Excision; Corticosteroids Dark brown 17 yrs Female
13 Kscar Sternum Skin irritation 12 yrs Excision Dark brown 39 yrs Female
14 Kscar Retroauricular − − None White 15 yrs Male
15 Kscar Pubic region Inflammation > 1 yr None Dark brown 46 yrs Female
16 Kscar Ear Surgery 4 yrs None White 11 yrs Female
sNskin was derived from normal skin directly adjacent to keloid scars
17 sNskin Pubic region − 6 yrs − Dark brown 19 yrs Female
13 sNskin Sternum Skin irritation 12 yrs Excision Dark brown 39 yrs Female
8 sNskin Abdomen − − − Dark brown 39 yrs Female
18 sNskin Breast Surgery > 1 yr None Dark brown 43 yrs Female
15 sNskin Pubic region Inflammation > 1 yr None Dark brown 46 yrs Female
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Immunohistochemical staining
Immunohistochemical stains were performed on deparaffi-
nized, formalin-fixed tissue sections to assess epidermal pro-
liferation (Ki67: clone MIB-1, Dakocytomation, Glostrup, 
Denmark; 1:50), epidermal differentiation (K10: keratin 
10, clone DE-K10, Progen, Heidelberg, Germany; 1:500 
and involucrin: clone SY5, Novocastra, New Castle, United 
Kingdom; 1:1000), presence of fibroblasts (vimentin: clone 
V9, Dakocytomation) and myofibroblasts (α-SMA: clone 
1A4, Dakocytomation). Supplementary antigen retrieval 
treatments were performed prior to incubation with the pri-
mary antibody using a 15 min. incubation step with pepsin 
(K10) and/or heat-induced antigen retrieval with 0.01M cit-
rate buffer pH 6.0 (Ki67, K10, K17, vimentin). Immunohis-
tochemical staining scoring (−) absence of staining; (+) nor-
mal staining pattern; (++) increased number of positively 
stained cells; (+++) strongly increased number of positively 
stained cells. Ki67 Proliferation index 100 basal cells were 
counted in three random locations in a tissue section (100× 
magnification), after which the number of positive cells 
along this length of the epidermis was counted. The prolif-
eration index was defined as the percentage of Ki67 positive 
nuclei within these regions.
Enzyme‑linked immunosorbent assay (ELISA)
Previously, we have identified a panel of wound healing 
mediators that are secreted predominantly by the epider-
mis (IL-1α, TNF-α, CCL5, VEGF), the dermis (TIMP2, 
HGF), or those significantly increased in the full thickness 
skin equivalents (CCL2, CXCL1, CXCL8, IL-6, sST2) 
[25]. CCL27 is found in burn wound exudates and has been 
implicated in the increased secretion of many of the afore-
mentioned proteins [31]. IL-18 was also included in this 
panel because it has previously been implicated in keloid 
formation [4] and is known to be expressed in reconstructed 
human skin models also [11].
Culture supernatants (1.5 ml KC-II without hydrocorti-
sone) derived from the skin models were collected over a 
24-h period at the end of the culture period (5 weeks) to 
measure the levels of IL-6 and CXCL8 (PeliKine Sanguin 
Reagents, Amsterdam, The Netherlands); CCL2, CCL5, 
CCL20, CCL27, CXCL1, HGF and VEGF (R&D System 
Inc., Minneapolis, MN, USA); and IL-18 (MBL Inter-
national, Woburn, MA, USA) secreted by the SE, using 
enzyme-linked immunosorbent assays (ELISA).
Quantitative polymerase chain reaction (qPCR)
For RNA isolation, the epidermis was removed from the der-
mis using a slide-warmer (40 °C), the dermis was then flash 
frozen and stored in liquid nitrogen until further processing. 
Samples were disrupted and homogenized in a TissueLyser, 
then flash frozen for storage at − 80 °C. RNA isolation was 
performed using QiaShredder™ kits and RNeasy® Mini 
kits with on-column DNAse digestion and stored at − 80 °C. 
The Nanodrop spectrophotometer (Nanodrop technologies, 
Wilmington, DE, USA) was used to measure total RNA 
concentration. cDNA was synthesized using the  RT2 First 
Strand Kit, while the  RT2 SYBR Green Fluor qPCR Master-
mix was used to run the real-time PCR reactions for the fol-
lowing genes (Table 2): COL4A2, HAS1 and MMP3. These 
three genes were selected because they showed differential 
expression between Nskin and Kscar in previous work [16]. 
The geometric mean of two housekeeping genes (ACTB and 
HPRT1) was used to normalize expression. Unless stated 
otherwise, all RNA and qPCR reagents were obtained from 
Qiagen GmbH (Hilden, Germany).
MTT assay
A colorimetric (MTT based) assay was used to quantify cell 
proliferation and viability (Roche Applied Science, Penz-
berg, Germany) of the skin models, as described previously 
[34].
Table 2  Overview of genes 
used for RT-PCR
An overview of the genes of interest (COL4A2, HAS1, MMP3) and the chosen housekeeping genes (ACTB, 
HPRT1). Listed here are gene symbols with full gene nomenclature and alternative synonymous gene 
names, matching UniGene (NCBI database of the transcriptome) cluster, and RefSeq (NCBI Reference 
Sequence project) number
Symbol Description Gene name UniGene RefSeq
ACTB Actin, beta BRWS1, PS1TP5BP1 Hs.520,640 NM_001101
HPRT1 Hypoxanthine phosphoribosyltransferase 1 HGPRT, HPRT Hs.412,707 NM_000194
COL4A2 Collagen, type IV, alpha 2 ICH, POREN2 Hs.508,716 NM_001846
MMP3 Matrix metallopeptidase 3 (stromelysin 1, 
progelatinase)
CHDS6, MMP-3, SL-1, 
STMY, STMY1, 
STR1
Hs.375,129 NM_002422
HAS1 Hyaluronan synthase 1 HAS Hs.57,697 NM_001523
819Archives of Dermatological Research (2018) 310:815–826 
1 3
Data analysis
Experiments were performed in duplicate with n ≥ 4 dif-
ferent donors, except for some of the immunohistochemi-
cal staining (one of duplicate skin models was stained: 
keratin 10, vimentin, α-SMA) and qPCR experiments; 
see Tables 1 and 3 for an overview of donor matching 
and the number of biological replicates used per experi-
ment. All results in graphs and tables were expressed as 
the mean ± standard error of the mean, PCR scatter plots 
showed the median. Normality testing (Shapiro–Wilk 
test) was performed on the residuals (errors); an ordinary 
one-way  ANOVA with Tukey’s multiple comparisons 
tests was employed if the residuals passed the normality 
test (epidermal thickness; dermal thickness; contraction; 
MTT; ECM gene expression; secretion of VEGF, CCL5, 
CXCL8), otherwise the Kruskall-Wallis test with Dunn’s 
multiple comparisons tests (Ki67; α-SMA; secretion of 
CCL2, CCL20, IL-18, CXCL1, IL-6, HGF, CCL27) was 
applied. For analysis of the PCR data, gene expression 
Fig. 1  Construction of skin models. a, b Keloids are dissected into: 
peripheral region (P), the central superficial (Cs) and central deep 
regions (Cd); the normal skin directly adjacent to the keloid periph-
ery (sN: surrounding normal skin). Keratinocytes and fibroblasts are 
isolated from each region (circles indicate where biopsies were taken 
for cell isolation) and combined to form a peripheral keloid (P-Kscar) 
model, central superficial keloid (Cs-Kscar) model, central deep 
keloid (Cd-Kscar) model, surrounding normal skin (sNskin) model 
(c). Skin models are constructed by first seeding fibroblasts into Mat-
riderm® (d). After 3 weeks, keratinocytes are added and the skin 
models are then cultured air-exposed for an additional 2 weeks
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 (2−∆Ct) was normalized with the geometric mean of two 
housekeeping genes (ACTB and HRPT1). Differences 
were considered significant if p < 0.05 (*), p < 0.01(**) 
or p < 0.001 (***). It should also be noted that due to our 
use of stringent statistical analysis for these small sample 
sizes, our results very likely show underestimation of true 
statistical significance. A correction for performing mul-
tiple comparisons was made using an ANOVA. Addition-
ally, the use of non-parametric tests in the event of non-
normal distribution of the residuals, although statistically 
correct, further reduced power. For this reason, the term 
‘trend’ was used when a clear pattern in graph data was 
observed without significance being reached; the exact p 
value was listed in the graph if 0.05 < p < 0.08. GraphPad 
Prism 6 software (GraphPad Software Inc., San Diego, 
CA, USA) was used to construct all graphs and tables and 
perform statistical analysis.
Results
Increased epidermal thickness in keloid models
Recently, we have shown that native keloids have 
increased epidermal thickness which was not related to 
hyperproliferation but may be related to abnormal involu-
crin expression [17]. Therefore, we first characterized the 
epidermal compartments of the keloid models (Fig. 2). All 
skin models showed a fully differentiated epidermis on a 
fibroblast-populated matrix. Cd-Kscar showed a significant 
increase in the number of epidermal keratinocyte layers 
compared to Nskin (Fig. 2b), with a similar trend occurring 
for Cs-Kscar (p = 0.0792). It should be noted that the differ-
ences described here were minor (1–2 cell layers) and not of 
the same magnitude as found in vivo (± 5 cell layers). sNskin 
showed similar results to unaffected Nskin.
In line with our previous findings on native tissue biop-
sies [17], there was no difference in the number of Ki67-
positive proliferating basal cells between the different skin 
models (10–15% of basal cells) and normal suprabasal 
keratin 10 expression was observed in all the experimental 
groups (lower panel Fig. 3). We previously reported that 
while involucrin expression in healthy skin is confined to 
the stratum granulosum, in native Kscar involucrin is over 
expressed in all suprabasal layers [17]. In all the skin models 
described in this study, suprabasal involucrin was observed 
and was not just limited to the keloid constructs.
Table 3  Overview of the donors 
used per experiment
Overview of the donors used per experiment and donor-matching between tissue samples
Nskin normal skin, P-Kscar peripheral keloid, Cs-Kscar central superficial keloid, Cd-Kscar central deep 
keloid, sNskin surrounding normal skin, x entire row of donors was used for the experiments listed, d donor 
number, RT-PCR reverse transcription polymerase chain reaction. Additional experiments include: contrac-
tion, epidermal thickness, dermal thickness, immunohistochemical stainings and ELISA
Nskin sNskin P-Kscar Cs-Kscar Cd-Kscar RT-PCR Additional 
experi-
ments
d1 x
d2 x
d3 x
d4 x
d5 x x
d6 x x
d7 x x
d8 d8 x x
d9 d9 d9 x
d10 d10 d10 x
d11 d11 d11 x x
d12 d12 d12 x x
d13 d13 d13 d13 x x
d14 d14 d14 x
d15 d15 x x
d16 d16 d16 x x
d17 x
d18 x x
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Increased contraction and α‑SMA expression 
in central keloid regions
Skin models constructed from all three different keloid 
scar regions showed a reduction in surface area and there-
fore increased contraction, compared to Nskin (Fig. 2a, c). 
sNskin was not significantly more contracted than Nskin. 
The increased contraction in Kscar was associated with the 
presence of myofibroblasts (Fig. 3). There was only little 
α-SMA staining in Nskin, sNskin and P-Kscar, but posi-
tive α-SMA staining was clearly present in Cs-Kscar and 
particularly Cd-Kscar. The difference in α-SMA expression 
was not the result of a disparity in the cellular contents of 
the dermis as there was no difference in vimentin staining 
between the models.
As increased thickness is one of the hallmarks of abnor-
mal scars, we also assessed dermal thickness in the skin 
models. However, none of the keloid models nor sNskin 
showed significantly increased dermal thickness compared 
to Nskin (Fig. 2d).
Keloid models show reduced dermal gene 
expression of collagen type IV α2
Cd-Kscar showed significantly decreased dermal expres-
sion of collagen type IV α2 (COL4A2) compared to Nskin 
(Fig. 4). sNskin showed intermediate levels of COL4A2 
expression between Nskin and Kscar. In contrast to COL4A2, 
no difference in gene expression of other extracellular matrix 
genes, matrix metallopeptidase 3 and hyaluronan synthase 
1, was observed between the skin models.
Secretion profiles of wound healing mediators
Next, we determined whether soluble wound healing media-
tors were differentially secreted by the keloid and normal 
skin models. HGF secretion was significantly decreased in 
Cd-Kscar compared to Nskin (Fig. 5). No significant dif-
ferences between the different keloid models, sNskin and 
Nskin were observed for the other inflammatory cytokines: 
CCL20, CCL27, CXCL8, IL-6, IL-18, CXCL1, CCL2 and 
CCL5 (Fig. 5). Cytokine secretion levels were not influenced 
by differences in viability between the skin models, as MTT 
values were not significantly different between groups (data 
not shown).
Discussion
In this study, we have used our previously published base-
line keloid model [16] to further investigate the underlying 
keloid pathogenesis. We tested the hypothesis that differ-
ences exist within keloids which contribute differentially to 
Fig. 2  Increased contraction, epidermal and dermal thickness in 
central keloid regions. Absolute surface area of the skin models was 
measured in duplicate in n = 8 normal skin (Nskin), n = 8 periph-
eral keloid (P-Kscar), n = 7 central superficial keloid (Cs-Kscar), 
n = 7 central deep keloid (Cd-Kscar), n = 5 surrounding normal skin 
(sNskin). a shows macroscopic views of SE at the start and end of 
culturing; b shows the number of viable epidermal cell layers in the 
SE; c shows the dermal thickness measured in µm; d shows contrac-
tion measured as a reduction in end surface area after 5 weeks of cul-
turing. *p < 0.05, if 0.05 > p < 0.08 then the exact p value is listed in 
the graph
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Fig. 3  Increased α-SMA stain-
ing in central keloid regions. 
Upper panel shows representa-
tive pictures of HE, α-SMA and 
vimentin stainings performed 
on one of the duplicate skin 
models in n = 8 normal skin 
(Nskin), n = 8 peripheral keloid 
(P-Kscar), n = 7 central super-
ficial keloid (Cs-Kscar), n = 7 
central deep keloid (Cd-Kscar), 
n = 5 surrounding normal skin 
(sNskin). Magnification 200×, 
scale bar 100 µm. Lower panel 
shows the results of immuno-
histochemical stainings of epi-
dermal markers (Ki67, keratin 
10), dermal cellular markers 
(vimentin, α-SMA) in the skin 
models. Ki67 is expressed as 
mean ± SEM; SPB: suprabasal 
expression; SB: stratum basale; 
PAN: panepidermal (both SB 
and SPB); +/−: minimal expres-
sion; +: normal expression; ++: 
increased expression; +++: 
strongly increased expression; 
–: absent
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keloid formation. Full thickness keloid scar models were 
constructed using keratinocytes and fibroblasts isolated from 
different regions within and around a keloid scar. Interest-
ingly, differences were observed in scar phenotype between 
the different keloid regions: of these, the central deep keloid 
Fig. 4  Differential dermal expression of ECM related genes. Dermal 
expression of COL4A2, MMP3 and HAS1 was determined in one of 
the duplicate skin models in n = 4 normal skin (Nskin), n = 5 periph-
eral keloid (P-Kscar), n = 4 central superficial keloid (Cs-Kscar), 
n = 4 central deep keloid (Cd-Kscar), n = 4 surrounding normal skin 
(sNskin). The scatter plots show the individual data points with the 
median, with *p < 0.05
Fig. 5  secretion of wound healing mediators. Wound healing media-
tor secretion of HGF, CCL27, CXCL8, CCL20, IL-6, IL-18, CCL5, 
CXCL1, VEGF, and CCL2 was determined in duplicate in n = 8 
normal skin (Nskin), n = 8 peripheral keloid (P-Kscar), n = 7 central 
superficial keloid (Cs-Kscar), n = 7 central deep keloid (Cd-Kscar), 
n = 5 surrounding normal skin (sNskin). Graphs show mean ± SEM, 
with *p < 0.05
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construct most often resembled the keloid phenotype, while 
the surrounding normal skin directly adjacent to the keloid 
showed a mixed normal skin and keloid scar phenotype.
Both the previously published baseline keloid model, 
as well as the central deep keloid model, showed increased 
contraction and α-SMA expression, decreased secretion of 
HGF, as well as decreased dermal expression of collagen 
type IV [16] compared to Nskin. Minor disparities between 
the two studies were found with regards to dermal MMP3 
and HAS1 expression as well as epidermal thickness. The 
baseline keloid model comprising the entire keloid showed 
no increase in epidermal thickness, but reduced COL4A2, 
HAS1 and MMP3 gene expression in the dermal compart-
ment of the keloid model compared to the normal skin 
model. In this study, we did observe an increase in epider-
mal thickness (albeit of a smaller magnitude than the native 
keloid tissue), but only collagen IV showed significantly 
reduced gene expression in the central deep keloid model 
(Cd-Kscar). We did not observe reduced MMP3 or HAS1 
gene expression. While the baseline keloid model showed a 
trend towards increased dermal thickness (p = 0.075), there 
was no statistically significant difference between the keloid 
regions and normal skin in this study. Either way, in both the 
baseline keloid model as well as the current keloid regions 
models, increased epidermal and dermal thickness are not 
as excessively present in our in vitro models compared to 
the in vivo keloids [17]. This may be due to the relatively 
short culture period (5 weeks) and only two skin cell types 
currently being present in the models. However, herein now 
lies the value of our in vitro scar model, as it allows for 
the relatively easy addition of other cell types (e.g. immune 
cells and endothelial cells) in the future in a controlled and 
scalable manner.
Most studies on keloid heterogeneity report an active, 
proliferating and invasive role for the keloid periphery [1, 5, 
12, 19, 24, 27, 33] compared to the quiescent centre. How-
ever, our results are in line with studies finding increased 
activity in the keloid central region [6, 21, 28]. To our 
knowledge, the only full thickness skin model constructed 
from keloid derived keratinocytes and fibroblasts from dif-
ferent regions within the keloid, was grafted into a mouse to 
develop a new keloid animal model [26]. Using superficial 
or deep keloid fibroblasts with keloid keratinocytes, two 
different keloid models were constructed and compared to 
normal skin model. After implantation into athymic mice, 
both keloid models were shown to be different from normal 
skin models (abnormal collagen organization) and differ-
ences were reported between superficial and deep keloid 
models. The deep keloid model had a thicker dermis and 
increased COL1A1 expression, while the superficial keloid 
model only showed an increased wound area after grafting. 
Based on the method of cell isolation described, the deep 
keloid model very likely comprises cells of our central deep 
keloid construct (Cd-Kscar) and as such, the aforementioned 
findings correspond to our results. Nonetheless, a human 
full thickness skin model representing keloid heterogeneity 
is not currently available. In that regard, our in vitro keloid 
models described here could serve as an excellent starting 
point for further research.
A possible explanation for the dichotomy in findings 
reporting either the periphery or the central keloid region 
as the driving force behind continued keloid growth may 
be because different keloid phenotypes exist. Bella et al. 
[2] suggested that differences in genetic abnormalities may 
be responsible for heterogeneity between keloids, and dis-
tinguished between ‘superficial spreading’ keloids versus 
‘raised’ keloids in an African tribe with familial keloids. 
In this regard, Supp et al. [26] also proposed an interesting 
model for the development of the ‘bulging’ keloid phenotype 
in which the deep keloid fibroblasts cause dermal thickening, 
while the superficial fibroblasts cause an increase in area 
by spreading the upper dermis (and overlying epidermis). 
The combination of deep dermal thickening and superficial 
dermal spreading then ultimately creates a ‘bulging’ keloid. 
Depending on the keloid phenotype, we propose that the 
actively growing region may be the periphery or the cen-
tre. This could explain why the periphery could very well 
be the actively expanding region in ‘spreading’ keloids, but 
not in the ‘bulging’ keloids where growth ensues from the 
deeper central regions. Retrospective analysis of the pictures 
of the keloid samples included in our study, in fact, showed 
that they were all of the ‘bulging’ phenotype. Three of the 
eight keloids used to construct the various keloid models 
were multinodular in appearance, consisting of several large 
dome-shaped nodules fused into a single large keloid. As the 
centre of each nodule was still more raised than the periph-
ery, these were also considered ‘bulging’ keloids. Given that 
all our keloid donors were of the ‘bulging’ phenotype, this 
could explain why only the central deep region was statisti-
cally significantly different from normal skin.
In this study, we also included extra-lesional normal skin 
(sNskin) directly adjacent to but separate from P-Kscar. 
Even though this surrounding normal skin (sNskin) did not 
show any statistically significant differences with the other 
models for the individual parameters studied, when taking 
all parameters together a clear pattern was emerging. sNskin 
was usually intermediate between normal skin and keloid 
in the expression of scar parameters and often similar to the 
peripheral keloid model (contraction; α-SMA expression; 
secretion of HGF; expression of COL4A2). Abnormalities 
in the surrounding normal skin (sNskin) have been previ-
ously reported. Lee et al. [15] found that the into the sur-
rounding normal skin. Using expression microarrays, Hahn 
et al. [7] found that increased expression of many of the 
genes in keloid-derived keratinocytes and fibroblasts corre-
sponded with similarly increased expression in cells derived 
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from adjacent non-lesional skin. However, we are unable 
to compare our results to the findings of others because it 
was often unclear what other authors considered to be sur-
rounding normal skin (sNskin). Definitions of sNskin could 
also mean the normal skin in the same anatomical location 
but not necessarily in the direct vicinity of the keloid and 
alternatively, sometimes the surrounding normal skin was 
included with the peripheral margin generating what we 
would consider an sNskin/P-Kscar region.
Notably, from all the parameters studied, significant dif-
ferences or trends were only obtained in a few parameters. 
This is indeed a limitation of the study and is most prob-
ably a result of the experimental set-up which could not be 
avoided. Surrounding normal skin was very rarely included 
with the keloid samples provided to us by the plastic sur-
geons, and when it was included, the keloid itself was often 
too small to enable adequate cell isolation from the differ-
ent keloid regions. Therefore, non-donor paired samples 
were included in the analysis. Additionally, small sample 
sizes are inherent to the time-consuming nature of tissue 
engineering. The problem with statistical analysis of small 
sample sizes (n < 24) is that one either errs on the side of 
over- or underestimation, depending on whether a correc-
tion is applied for performing multiple comparisons. In this 
study, we had small sample sizes and corrected for multiple 
comparisons using a one-way ANOVA, power was further 
reduced in our study by our use of non-parametric testing 
when the residuals were not normally distributed. Thus, we 
have been relatively strict with our statistics to the point 
of underestimation, but consider this the better option as 
opposed to risking overestimation.
To conclude, we were able to generate different keloid 
scar models from keratinocytes and fibroblasts derived 
from intralesional peripheral, central superficial and central 
deep regions, as well as extralesional surrounding normal 
skin. Of these regions, only the central deep keloid regions 
showed statistically significant differences when compared 
to normal skin and thus displayed the most aberrant behav-
ior. As all the keloid cells were derived from ‘bulging’ type 
keloids, this suggests that the central deep keloid region is 
likely the driving force behind the development of keloids 
of this ‘bulging’ phenotype. Our study has demonstrated 
the need for a clear and unambiguous description of the 
keloid type (e.g. ‘spreading’ or ‘bulging’) and of the exact 
location within keloid scars from which samples are taken. 
Additionally, we would encourage the inclusion of the skin 
adjacent to the keloids, as it is important to find out to what 
extent this region contributes to keloid scar formation and 
consequently if it should be targeted for treatment as well. 
This study is the first demonstration of how the in vitro base-
line keloid scar model we have previously established [16] 
can be utilized not only as a future animal-free drug testing 
platform but also to further our understanding of the under-
lying pathogenesis.
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